肝硬化失代偿期并发自发性细菌性腹膜炎危险因素分析及治疗
Risk Factors Analysis and Treatment of Spontaneous Bacterial Peritonitis in Decompensated Cirrhosis
DOI: 10.12677/MD.2022.122027, PDF,   
作者: 李倩倩, 芦永福, 王学红:青海大学附属医院,青海 西宁
关键词: 肝硬化自发性腹膜炎危险因素治疗Cirrhosis Spontaneous Peritonitis Risk Factor Treatment
摘要: 自发性腹膜炎是肝硬化腹水患者一种常见而严重的并发症,是肝硬化腹水患者死亡的主要原因之一。但其发病机制处于未知,目前认为细菌移位是发病重要环节,其致病菌大多数为肠道菌群,常无腹痛、发热等典型腹膜炎症状,早期诊断是治疗的关键,本文旨在分析肝硬化失代偿期合并自发性细菌性腹膜炎密切相关且容易忽略危险因素及治疗,在临床工作中可以及早发现对患者的潜在威胁因素,对疾病的预防、治疗和预后具有重要意义。
Abstract: Spontaneous peritonitis is a common and serious complication in cirrhotic ascites and is one of the main causes of death in cirrhotic ascites. But its pathogenesis is unknown, now think that the onset of bacterial translocation is the important link, its most for intestinal pathogenic bacteria, often without abdominal pain, fever and other typical symptoms of peritonitis, early diagnosis is the key to the treatment, the purpose of this paper is to analyze cirrhosis of the liver decompensation period is closely related with spontaneous bacterial peritonitis and easy to ignore the risk factors and treatment, In clinical work, the potential threat factors to patients can be found early, which is of great significance to the prevention, treatment and prognosis of diseases.
文章引用:李倩倩, 芦永福, 王学红. 肝硬化失代偿期并发自发性细菌性腹膜炎危险因素分析及治疗[J]. 医学诊断, 2022, 12(2): 172-179. https://doi.org/10.12677/MD.2022.122027

参考文献

[1] 单姗, 赵连晖, 马红, 欧晓娟, 尤红, 贾继东. 肝硬化的定义、病因及流行病学[J]. 临床肝胆病杂志, 2021, 37(1): 14-16.
[2] Ginés, P., Quintero, E., Arroyo, V., Terés, J., Bruguera, M., Rimola, A., Caballería, J., Rodés, J. and Roz-man, C. (1987) Compensated Cirrhosis: Natural History and Prognostic Factors. Hepatology, 7, 122-128. [Google Scholar] [CrossRef] [PubMed]
[3] 朱龙川, 甘达凯, 胡青青, 熊墨龙. 第三代头孢菌素耐药的自发性细菌性腹膜炎发生的预测因素[J]. 临床肝胆病杂志, 2019, 35(7): 1501-1504.
[4] Aljumah, A.A., Selayem, N.B., Al-Howti, S.Y., Dafallah, M., AlGhamdi, H., Mokhtar, H., et al. (2018) Clinical and Virological Outcomes of Entecavir Therapy in Patients with Chronic Hepatitis B: A Real Life Experience. Journal of Infection and Chemotherapy, 25, 12-16. [Google Scholar] [CrossRef] [PubMed]
[5] Singal, A.K., Salameh, H. and Kamath, P.S. (2014) Prevalence and In-Hospital Mortality Trends of Infections among Patients with Cirrhosis: A Nationwide Study of Hospitalized Patients in the United States. Alimentary Pharmacology & Therapeutics, 40, 105-112. [Google Scholar] [CrossRef] [PubMed]
[6] Tay, P.W.L., Xiao, J., Tan, D.J.H., Ng, C., Lye, Y.N., Lim, W.H., et al. (2021) An Epidemiological Meta-Analysis on the Worldwide Prevalence, Resistance, and Outcomes of Spontaneous Bacterial Peritonitis in Cirrhosis. Frontiers in Medicine, 8, Article ID: 693652. [Google Scholar] [CrossRef] [PubMed]
[7] Wang, Y. and Zhang, Q. (2018) Analysis of Risk Factors for Pa-tients with Liver Cirrhosis Complicated with Spontaneous Bacterial Peritonitis. Iranian Journal of Public Health, 47, 1883-1890.
[8] Marciano, S., Díaz, J.M., Dirchwolf, M. and Gadano, A. (2019) Spontaneous Bacterial Peritonitis in Patients with Cirrhosis: Incidence, Outcomes, and Treatment Strategies. Hepatic Medicine: Evidence and Research, 11, 13-22. [Google Scholar] [CrossRef
[9] 申红霞, 娄小平, 苌新伟, 郑晓, 杜文婷, 赵贝贝, 王文娟. 肝硬化患者自发性细菌性腹膜炎危险因素的Meta分析[J]. 世界华人消化杂志, 2016, 24(12): 1903-1909.
[10] 倪传斌, 陈武军. 80例肝硬化腹水并发自发性细菌性腹膜炎高危因素分析[J]. 中国热带医学, 2013, 13(12): 1514-1516
[11] 冯梦蝶. 肝硬化合并自发性细菌性腹膜炎27例高危因素分析[J]. 海南医学, 2012, 23(13): 72-74.
[12] Thomson, M.J., Tapper, E.B. and Lok, A.S. (2018) Dos and Don’ts in the Management of Cirrhosis: A View from the 21st Centu-ry. American Journal of Gastroenterology, 113, 927-931. [Google Scholar] [CrossRef] [PubMed]
[13] Granito, A. and Bolondi, L. (2017) Non-Transplant Therapies for Patients with Hepatocellular Carcinoma and Child-Pugh-Turcotte Class B Cirrhosis. Lancet Oncology, 18, E101-E112. [Google Scholar] [CrossRef
[14] 黎倍伶, 钟国涛, 陈金军. 自发性细菌性腹膜炎诊断和治疗现状[J]. 临床肝胆病杂志, 2019, 35(9): 2079-2081.
[15] 邓媛, 廖毅. 慢性肝炎肝硬化腹水并发自发性细菌性腹膜炎相关危险因素分析[J]. 中国基层医药, 2011, 18(16): 2182-2183
[16] Huang, C.H., Lin, C.Y., Sheen, I.S., Chen, W.-T., Lin, T.-N., Ho, Y.-P., et al. (2011) Recurrence of Spontaneous Bacterial Peritonitis in Cirrhotic Patients Non Prophylactically Treated with Norfloxacin: Serum Albumin as an Easy but Reliable Predictive Factor. Liver Interna-tional, 31, 184-191. [Google Scholar] [CrossRef] [PubMed]
[17] Lee, S., Saxinger, L., Ma, M., Prado, V., Fernández, J., Kumar, D., et al. (2017) Bacterial Infections in Acute Variceal Hemorrhage Despite Antibiotics—A Multicenter Study of Predictors and Clinical Impact. United European Gastroenterology Journal, 5, 1090-1099. [Google Scholar] [CrossRef] [PubMed]
[18] 武瑞, 刘春涛, 傅晓晴, 刘寿荣. 非选择性β-受体阻滞剂对失代偿肝硬化患者循环及肾损伤的影响研究[J]. 中国现代医生, 2018, 56(25): 5-9.
[19] Gyu, J.B., Cheul, L.W., Young, J.J., Jeong, S.W., Kim, Y.D., Cheon, G.J., et al. (2018) Follow-up Creatinine Level Is an Important Predictive Factor of In-Hospital Mortality in Cirrhotic Patients with Spontaneous Bacterial Peritonitis. Journal of Korean Medical Science, 33, e99. [Google Scholar] [CrossRef] [PubMed]
[20] Schrier, R.W., Arroyo, V., Bernardi, M., Epstein, M., Henriksen, J.H. and Rodés, J. (1998) Peripheral Arterial Vasodilation Hypothesis: A Proposal for the Initiation of Renal Sodium and Water Retention in Cirrhosis. Hepatology, 8, 1151-1157. [Google Scholar] [CrossRef] [PubMed]
[21] Fasolato, S., Angeli, P., Dallagnese, L., Maresio, G., Zola, E., Mazza, E., et al. (2010) Renal Failure and Bacterial Infections in Patients with Cirrhosis: Epidemiology and Clinical Features. Hepatology, 45, 223-229. [Google Scholar] [CrossRef] [PubMed]
[22] Follo, A., Llovet, J.M., Navasa, M., Planas, R., Forns, X., Francitorra, A., et al. (1994) Renal Impairment after Spontaneous Bacterial Peritonitis in Cirrhosis: Incidence, Clinical Course, Predictive Factors and Prognosis. Hepatology, 20, 1495-1501. [Google Scholar] [CrossRef] [PubMed]
[23] Tandon, P. and Garcia-Tsao, G. (2011) Renal Dysfunction is the Most Important Independent Predictor of Mortality in Cirrhotic Patients with Spontaneous Bacterial Peritonitis. Clinical Gastroenterology and Hepatology, 9, 260-265. [Google Scholar] [CrossRef] [PubMed]
[24] Imhann, F, Bonder, M.J., Vila, A.V., Fu, J., Mujagic, Z., Vork, L., et al. (2016) Proton Pump Inhibitors Affect the Gut Microbiome. Gut, 65, 740-748. [Google Scholar] [CrossRef] [PubMed]
[25] Brandl, K. and Schnabl, B. (2015) Is Intestinal Inflammation Linking Dysbiosis to Gut Barrier Dysfunction during Liver Disease? Expert Review of Gastroenterology & Hepatology, 9, 1069-1076. [Google Scholar] [CrossRef] [PubMed]
[26] Bajaj, J.S., Chathur, A., Andrew, F., White, M.B., Gavis, E., Heuman, D.M., et al. (2018) Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis. American Journal of Gastroenterology, 113, 1177-1186. [Google Scholar] [CrossRef] [PubMed]
[27] European Association for the Study of the Liver (2018) EASL Clinical Practice Guidelines for the Management of Patients with Decompensated Cirrhosis. Journal of Hepatology, 69, 406-460. [Google Scholar] [CrossRef] [PubMed]
[28] Komolafe, O., Roberts, D., Freeman, S.C., Wilson, P., Sutton, A.J., Cooper, N.J., Pavlov, C.S., Milne, E.J., Hawkins, N., Cowlin, M., Thorburn, D., Davidson, B.R., Tsochat-zis, E. and Gurusamy, K.S. (2020) Antibiotic Prophylaxis to Prevent Spontaneous Bacterial Peritonitis in People with Liver Cirrhosis: A Network Meta-Analysis. Cochrane Database of Systematic Reviews, Article No. CD013125. [Google Scholar] [CrossRef
[29] Li, Y.-T., Yu, C.-B., Huang, J.-R., Qin, Z.-J. and Li, L.-J. (2015) Pathogen Profile and Drug Resistance Analysis of Spontaneous Peritonitis in Cirrhotic Patients. World Journal of Gastroenterology, 21, 10409-10417. [Google Scholar] [CrossRef] [PubMed]
[30] Ding, X., Yu, Y.H., Chen, M., Wang, C., Kang, Y.F. and Lou, J.L. (2019) Causative Agents and Outcome of Spontaneous Bacterial Peritonitis in Cirrhotic Patients: Community-Acquired versus No Socomial Infections. BMC Infectious Diseases, 19, Article No. 463. [Google Scholar] [CrossRef] [PubMed]
[31] Campillo, B., Dupeyron, C. and Richardet, J.P. (2001) Epidemi-ology of Hospital-Acquired Infections in Cirrhotic Patients: Effect of Carriage of Methicillin-Resistant Staphylococcus aureus and Influence of Previous Antibiotic Therapy and Norfloxacin Prophylaxis. Epidemiology & Infection, 127, 443-450. [Google Scholar] [CrossRef
[32] Fiore, M., Gentile, I., Maraolo, A.E., Leone, S., Sim-eon, V., Chiodini, P., et al. (2018) Are Third-Generation Cephalosporins Still the Empirical Antibiotic Treatment of Community-Acquired Spontaneous Bacterial Peritonitis? A Systematic Review and Meta-Analysis. European Journal of Gastroenterology & Hepatology, 30, 329-336. [Google Scholar] [CrossRef
[33] Campillo, B., Dupeyron, C., Richardet, J.P., Mangeney, N. and Leluan, G. (1998) Epidemiology of Severe Hospital-Acquired Infections in Patients with Liver Cirrhosis: Effect of Long-Term Administration of Norfloxacin. Clinical Infectious Diseases, 26, 1066-1070. [Google Scholar] [CrossRef] [PubMed]
[34] Lutz, P., Nischalke, H.D., Krämer, B., Goeser, F., Kaczmarek, D.J., Schlabe, S., et al. (2017) Antibiotic Resistance in Healthcare-Related and Nosocomial Spontaneous Bacterial Peritonitis. European Journal of Clinical Investigation, 47, 44-52. [Google Scholar] [CrossRef] [PubMed]
[35] Rostkowska, K.A., Szy-manek-Pasternak, A. and Simon, K.A. (2018) Spontaneous Bacterial Peritonitis—Therapeutic Challenges in the Era of Increasing Drug Resistance of Bacteria. Clinical & Experimental Hepatology, 4, 224-321. [Google Scholar] [CrossRef] [PubMed]
[36] Piano, S., Fasolato, S., Salinas, F., Romano, A., Tonon, M., Morando, F., et al. (2016) The Empirical Antibiotic Treatment of Nosocomial Spontaneous Bacterial Peritonitis: Results of a Ran-domized, Controlled Clinical Trial. Hepatology, 63, 1299-1309. [Google Scholar] [CrossRef] [PubMed]
[37] Tariq, T., Irfan, F.B., Farishta, M., Dykstra, B., Sieloff, E.M. and Desai, A.P. (2019) Spontaneous Fungal Peritonitis: Mi-cro-Organisms, Management and Mortality in Liver Cirrhosis—A Systematic Review. World Journal of Hepatology, 11, 596-606. [Google Scholar] [CrossRef] [PubMed]
[38] Liang, S., Webb, T. and Li, Z. (2014) Probiotic Antigens Stimulate Hepatic Natural Killer T Cells. Immunology, 141, 203-210. [Google Scholar] [CrossRef] [PubMed]
[39] Macnaughtan, J., Figorilli, F., García-López, E., Lu, H., Jones, H., Sawhney, R., et al. (2020) A Double-Blind, Randomized Placebo-Controlled Trial of Probiotic Lactobacillus casei Shi-rota in Stable Cirrhotic Patients. Nutrients, 12, Article No. 1651. [Google Scholar] [CrossRef] [PubMed]
[40] Sánchez, E., Nieto, J.C., Vidal, S., Santiago, A., Martinez, X., Sancho, F.J., et al. (2017) Fermented Milk Containing Lactobacil-lus paracasei subsp. paracasei CNCM I-1518 Reduces Bacterial Translocation in Rats Treated with Carbon Tetrachlo-ride. Scientific Reports, 7, Article No. 45712. [Google Scholar] [CrossRef] [PubMed]
[41] Pande, C., Kumar, A. and Sarin, S.K. (2012) Addition of probiotics to norfloxacin does not improve efficacy in the Prevention of Spontaneous Bacterial Peritonitis: A Double-Blind Placebo-Controlled Randomized-Controlled Trial. European Journal of Gastroen-terology & Hepatology, 24, 831-839. [Google Scholar] [CrossRef
[42] Mücke, M.M., Mücke, V.T., Graf, C., et al. (2020) Efficacy of Norfloxacin Prophylaxis to Prevent Spontaneous Bacterial Peritonitis: A System-atic Review and Meta-Analysis. Clinical and Translational Gastroenterology, 11, Article No. e00223. [Google Scholar] [CrossRef] [PubMed]
[43] Ginès, P., Tito, L.V., Arroyo, V., Planas, R., Panés, J., Viver, J., et al. (1988) Randomized Comparative Study of Therapeutic Paracentesis with and without Intravenous Albumin in Cirrhosis. Gastroenterology, 94, 1493-1502. [Google Scholar] [CrossRef] [PubMed]
[44] Sort, P., Navasa, M., Arroyo, V., Aldeguer, X., Planas, R., Ruiz-del-Arbol, L., et al. (1999) Effect of Intravenous Albumin on Renal Impairment and Mortality in Patients with Cir-rhosis and Spontaneous Bacterial Peritonitis. The New England Journal of Medicine, 341, 403-409. [Google Scholar] [CrossRef
[45] Shalaby, S.M., Baiumy, E.M., Abdelrahman, M.G., Sayed, M.M., Abdelhalim, R.M. and Amer, A.A. (2020) Assessment of Serum 25-Hydroxy Vitamin D in Cirrhotic Patients with and without Spontaneous Bacterial Peritonitis (SBP). QJM: An International Journal of Medicine, 113, hcaa052.015. [Google Scholar] [CrossRef
[46] Philips, C.A., Pande, A., Shasthry, S.M., Jamwal, K.D., Khillan, V., Chandel, S.S., et al. (2016) Healthy Donor Fecal Microbiota Transplantation in Steroid Ineligible Severe Alcoholic Hepatitis—A Pilot Study. Clinical Gastroenterology and Hepatology, 15, 600-602. [Google Scholar] [CrossRef] [PubMed]
[47] Bajaj, J.S., Salzman, N.H., Acharya, C., Sterling, R.K., White, M.B., Gavis, E.A., et al. (2019) Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Ran-domized, Placebo-Controlled Trial. Hepatology, 70, 1690-1703. [Google Scholar] [CrossRef] [PubMed]
[48] 徐元红, 宋传芳, 周志坚, 张杰, 庄彦华. 粪菌移植治疗肝硬化合并细菌性自发性腹膜炎的临床疗效[J]. 牡丹江医学院学报, 2017, 38(1): 56-57+70.